Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Cavanaugh · SciRah

Researcher profile · Semantic Scholar

J. Cavanaugh

Share profile

J. Cavanaugh — researcher profile on SciRah

h-index: 8
Works: 61
Citations: 381

Most-cited papers

Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
2013207 citations
Semantic Scholar
Pharmacist-coordinated multidisciplinary hospital follow-up visits improve patient outcomes.
J. Cavanaugh, Kimberly N Lindsey, B. Shilliday, S. Ratner
2015Journal of Managed Care & Specialty Pharmacy56 citations Open access
Semantic Scholar
Medicare annual wellness visits conducted by a pharmacist in an internal medicine clinic.
Keith Warshany, Christina H. Sherrill, J. Cavanaugh, T. Ives +1 more
2014American Journal of Health-System Pharmacy34 citations
Semantic Scholar
Implementation Science Workshop: Primary Care-Based Multidisciplinary Readmission Prevention Program
J. Cavanaugh, Christine D. Jones, Genevieve G R Embree, Katy K. Tsai +7 more
2014Journal of general internal medicine34 citations Open access
Semantic Scholar
Patient Satisfaction with Medicare Annual Wellness Visits Administered by a Clinical Pharmacist Practitioner.
Christina H. Sherrill, J. Cavanaugh, B. Shilliday
2017Journal of Managed Care & Specialty Pharmacy16 citations Open access
Semantic Scholar
Community Pharmacist Preferences in Transition of Care Communications
Mackenzie A. Dolan, C. Renfro, S. Ferreri, B. Shilliday +2 more
2019Journal of pharmacy and practice10 citations
Semantic Scholar
Impact of pharmacist participation in the patient care team on value-based health measures.
Michael Patti, Evan W. Colmenares, A. Abrahamson, Sarah Weddle +3 more
2022American Journal of Health-System Pharmacy8 citations Open access
Semantic Scholar
Psychological and pharmacological treatments for adults with posttraumatic stress disorder: A systematic review and meta-analysis
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +9 more
20138 citations
Semantic Scholar
Advancing Pharmacy Practice through an Innovative Ambulatory Care Transitions Program at an Academic Medical Center
J. Cavanaugh, N. Pinelli, Stephen F. Eckel, Mark D. Gwynne +2 more
2020Pharmacy5 citations Open access
Semantic Scholar
Outcomes of Aural Rehabilitation Provided in Person or by Telehealth Among Deaf/Hard of Hearing Young Children with Cochlear Implants or Hearing Aids
Jim Grigsby, Anu Sharma, Arlene Stredler-Brown, J. Cavanaugh +7 more
2024Telemedicine journal and e-health2 citations Open access
Semantic Scholar
Frontline perspective on credentialing and privileging of ambulatory care pharmacists
Zachary A. Weber, Jessica W. Skelley, D. Riche, Betsy Bryant Shilliday +2 more
2020International Journal of Pharmacy Practice1 citations Open access
Semantic Scholar
Table 37, Characteristics of included studies directly comparing psychotherapy with pharmacotherapy
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 31, Characteristics of included placebo-controlled trials of SNRIs
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table D, Summary of findings and strength of evidence for efficacy of pharmacological treatments for improving PTSD symptoms, achieving remission, and improving depression symptoms
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 21, Loss of PTSD diagnosis for narrative exposure therapy compared with inactive controls
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 3, Eligibility criteria
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 32, Characteristics of placebo-controlled trials of tricyclic antidepressants excluded because of high risk of bias
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 11, Mean change from baseline in PTSD symptoms for exposure therapy compared with stress inoculation training
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure B, Disposition of articles
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 15, Mean change from baseline in CAPS for CBT-mixed interventions compared with control, by comparator
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 19, Mean change from baseline in depression symptoms for EMDR compared with control, by type of comparator
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table A, Diagnostic criteria (DSM-IV-TR) for posttraumatic stress disorder
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 40, Characteristics of trials assessing combinations of treatments compared with either one alone excluded from main analyses because of high risk of bias
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 23, Characteristics of included placebo-controlled trials of alpha-blockers
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 6, Mean change from baseline to end of treatment in PTSD symptoms (any measure) for exposure therapy compared with control, by type of comparator
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table C, Summary of findings and strength of evidence for comparative effectiveness of psychological treatments for improving PTSD symptoms, achieving loss of PTSD diagnosis, and improving depression symptoms
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 21, Characteristics of other psychological intervention trials excluded from main analyses because of high risk of bias
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 45, Results of risk difference calculations for specific adverse events: paroxetine compared with placebo
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 27, Characteristics of placebo-controlled trials of atypical antipsychotics excluded from main analyses because of high risk of bias
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Outcome Measures and Instruments
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 20, Characteristics of included studies of other psychological interventions
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 28, Characteristics of placebo-controlled trials of benzodiazepines excluded from main analyses because of high risk of bias
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 39, Characteristics of included trials assessing combinations of treatments compared with either one alone
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 46, Results of meta-analyses and risk difference calculations for specific adverse events: sertraline compared with placebo
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 17, Results at end of treatment for disability or functional impairment outcomes for CBT-mixed interventions compared with inactive controls
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 30, Characteristics of placebo-controlled trials of SSRIs excluded from main analyses because of high risk of bias
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 5, Common outcome measures used in the included trials
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 25, Mean change from baseline in CAPS for venlafaxine ER compared with placebo
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 7, Sensitivity analysis for mean change from baseline to end of treatment in PTSD symptoms (any measure) for exposure therapy compared with control, by type of comparator: including present-centered therapy comparators and high risk of bias studies
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table E-1, Quality ratings for efficacy/effectiveness trials
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 8, Characteristics of included cognitive therapy trials
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 24, Characteristics of included placebo-controlled trials of anticonvulsants, by drug
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 23, Mean change from baseline in CAPS for SSRIs compared with placebo
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 16, Loss of PTSD diagnosis for CBT-mixed interventions compared with control, by type of comparator
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 26, Characteristics of included placebo-controlled trials of atypical antipsychotics, by drug
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 8, Mean change from baseline in CAPS for exposure therapy compared with cognitive therapy
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 4, Loss of PTSD diagnosis for cognitive processing therapy compared with controls, by type of comparator
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 3, Mean change from baseline in CAPS for cognitive processing therapy compared with controls, by type of comparator
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Table 15, Characteristics of included CBT-mixed intervention trials
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar
Figure 10, Mean change in Beck Depression Inventory for exposure therapy compared with cognitive therapy
D. Jonas, K. Cusack, C. Forneris, Tania M. Wilkins +10 more
20130 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Jonas×41
Invite
D. Jonas — researcher profile on SciRah
K. Cusack×41
Invite
K. Cusack — researcher profile on SciRah
C. Forneris×41
Invite
C. Forneris — researcher profile on SciRah
Tania M. Wilkins×41
Invite
Tania M. Wilkins — researcher profile on SciRah

×41

Invite

J. Sonis — researcher profile on SciRah

J. Middleton×41

Invite

J. Middleton — researcher profile on SciRah

D. Meredith×41

Invite

D. Meredith — researcher profile on SciRah

K. Brownley×41

Invite

K. Brownley — researcher profile on SciRah

K. R. Olmsted×41

Invite

K. R. Olmsted — researcher profile on SciRah

A. Greenblatt×41

Invite

A. Greenblatt — researcher profile on SciRah

Invite

A. Weil — researcher profile on SciRah

Invite

B. Gaynes — researcher profile on SciRah